Award Data

Osteoporosis is a major community health problem for which several effective FDA approved therapies exist, but which remains largely undiagnosed and untreated. While bone densitometry using dual-energy x-ray absorptiometry (DXA) is the current "gold standard" in osteoporosis diagnosis, controlled clinical trials have highlighted its sensitivity and specificity limitations at the individual patient ...

DESCRIPTION (provided by applicant): Octagen's broad, long-term objective is to complete the clinical development and secure FDA approval of its b-domain deleted recombinant factor VIII (OBI-1), a low antigenicity version of factor VIM (fVIII). OBI-1 is designed for the treatment of patients with inhibitory, neutralizing antibodies to human fVIII. Such "inhibitor" patients include congenital hemop ...

DESCRIPTION (provided by applicant): The incidence of healthcare-acquired infections has increased significantly in recent years and has become an important cause of morbidity and mortality in hospitals in the US and worldwide. The continuing emergence of drug resistance in clinically-important pathogens has now become a global problem and public health threat. In a 2003 Institute of Medicine repo ...

DESCRIPTION (provided by applicant): ProlX Pharmaceuticals, a company focusing on redox targets for development of anti-cancer therapies, has identified PX-478 as a novel hypoxia inducible factor (HIF) inhibitor and hypoxic bystander anti-cancer agent. The initial Phase I SBIR proposal, with aims to synthesize and evaluate novel agents that would be activated within a hypoxic tumor environment, pr ...

DESCRIPTION (provided by applicant): 4,4'-Dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) was originally developed as an immune modulator of immune deficiency associated cancerous growths. In a recent study, A-007 was administered as a topical gel to treat anogenital cancers associated with the human papillomavirus (HPV). There were no local or systemic toxicities and excellent responses ...

DESCRIPTION (provided by applicant): This is a competing continuation application of our SBIR Phase II project entitled "Effective and Non-Toxic Antagonist to Heparin and LMWH". Extremely promising results and outstanding productivity have been attained from the previous Phase II research, as reflected by the publication of 12 peer-reviewed manuscripts and 2 US patents. Both in vitro and animal te ...

DESCRIPTION (provided by applicant): Unlike adults, neonates cannot undergo traditional mental status testing (orientation, language, memory, etc.) as a measure of cortical function. However, the use of EEG is well established as one of the only semi-objective means to characterize the health of the cerebral cortex in neonates. Unfortunately, the availability of expert neonatal EEG interpretation ...

DESCRIPTION (provided by applicant): The principal objective of this application is to establish a new methodology for the early detection of abnormal lesions, whether pre-cancerous or cancerous, in breast imaging. Early detection is crucial to identifying lesions while they are still contained when the cure rate is near 100%. Existing mammography often does not identify lesions until significant ...

DESCRIPTION (provided by applicant): This Phase II project will advance to the clinical stage the novel pharmacologic agent GLY-022 for microvascular complications of diabetes by expanding in vivo studies on nephropathy to the streptozotocin diabetic rat and on retinopathy in the STZ-diabetic rat and in the db/db mouse, by assessing bioavailability, pharmacokinetics, and acute lethality, and by co ...

DESCRIPTION (provided by applicant): We propose to launch the first commercial service enabling physicians at unaffiliated hospitals to directly retrieve their patients' digital images and reports from each other on-demand. Despite significant societal need and market demand, US hospitals remain islands of mutually inaccessible data even as patients move between them. Even the most vulnerable p ...